Addyi Cost in New York 2026: Price, Insurance, Medicaid, and Compounding Options

What Is the Retail Price of Addyi in New York in 2026?

The manufacturer list price for a 30-tablet supply of Addyi (flibanserin 100 mg, Sprout Pharmaceuticals) is $880 per month at New York retail pharmacies in 2026. That price has held roughly stable since 2022 and reflects the brand-only market: the FDA has not yet approved a generic flibanserin tablet. Without insurance or a savings program, most New York patients pay close to that $880 figure at chains such as CVS, Walgreens, and Duane Reade.

Flibanserin was approved by the FDA on August 18, 2015, for hypoactive sexual desire disorder (HSDD) in premenopausal women under a Risk Evaluation and Mitigation Strategy (REMS) because of a clinically significant interaction with alcohol and certain CYP3A4 inhibitors [1]. The prescriber, pharmacy, and patient must all be enrolled in the Addyi REMS program before a prescription can be dispensed.

Real-world out-of-pocket costs vary. GoodRx and similar coupon platforms occasionally list discounted cash prices between $780 and $850 at select New York pharmacies, but these programs do not stack with insurance. For most commercially insured New York patients, the actual cost after a plan copay or coinsurance ranges from $0 to $150 per month, depending on tier placement.

Does New York Medicaid Cover Addyi?

New York Medicaid covers Addyi, but prior authorization (PA) is required in 2026. Prescribers must document that the diagnosis of HSDD meets clinical criteria, that the patient is premenopausal, that there is no ongoing alcohol use disorder, and that contraindicated medications such as fluconazole or combined hormonal contraceptives containing CYP3A4-inhibiting components have been reviewed [2].

The PA process typically takes 3 to 10 business days through New York State Medicaid Managed Care plans. Prescribers can submit documentation through the eMedNY portal or through the individual managed care organization (MCO) handling the patient's coverage.

If the initial PA is denied, a prescriber-submitted appeal citing the BEGONIA trial data and the FDA-approved indication carries meaningful weight. The BEGONIA trial (N=1,378, published in J Sex Med 2014) demonstrated that flibanserin 100 mg nightly increased the number of satisfying sexual events (SSEs) by 0.7 to 1.0 event per 28 days over placebo and reduced distress scores on the Female Sexual Distress Scale-Revised at 24 weeks [3]. Those data form the core of the FDA-approved label and are the best clinical anchor for a PA appeal.

New York's Medicaid Drug Utilization Review (DUR) board periodically reassesses prior authorization criteria, so prescribers should confirm current requirements at the eMedNY clinical edits page before submitting.

Which Commercial Insurance Plans in New York Cover Addyi?

Coverage varies sharply by insurer and plan tier. The following applies broadly to large commercial carriers operating in New York as of mid-2025.

Empire BlueCross BlueShield: Addyi appears on some formularies as a Tier 3 specialty drug, requiring step therapy documentation showing that the patient has been counseled on non-pharmacologic management (typically mindfulness-based sex therapy per American College of Obstetricians and Gynecologists guidance) [4].

UnitedHealthcare (NY plans): Flibanserin is covered on select UHC Choice Plus and UHC Manage formularies with PA; the PA form requests documented HSDD diagnosis duration of at least four weeks and absence of contraindications.

Aetna (NY state plans): Covered with PA on commercial plans; not covered on Aetna Medicare Advantage (Addyi is indicated only for premenopausal women, so Medicare eligibility is uncommon).

Oscar Health / MetroPlus: Coverage status changes at each annual formulary review. Patients should verify status on the plan's drug formulary tool or request a formulary exception in writing.

The out-of-pocket benchmark: patients who clear PA on a commercial plan in New York typically pay a Tier 3 or Tier 4 specialty copay of $50 to $150 per month before the plan's out-of-pocket maximum resets each January.

How Does the Sprout Pharmaceuticals Savings Card Work in New York?

Sprout Pharmaceuticals offers a manufacturer co-pay savings card that can reduce monthly cost to as low as $10 for eligible commercially insured patients in New York. The program does not apply to patients covered by any federal or state government program, including New York Medicaid, Medicare, or CHIP.

Eligible patients enroll at the Addyi savings portal (addyi.com/savings) and receive a card number to present at the pharmacy alongside their prescription. The program caps annual savings at a set dollar ceiling, which Sprout adjusts periodically. As of the 2025 program year, the ceiling covered up to $750 per fill for a maximum of 12 fills per year, effectively making the drug free or near-free for patients whose commercial plan reimburses it at any tier.

New York patients should call Sprout's patient support line (1-844-MYADDYI) to confirm current program terms before filling the first prescription, because the ceiling and eligibility criteria have changed twice since 2020.

Is Compounded Flibanserin Legal in New York?

Yes. Compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act can legally compound flibanserin in New York, provided they meet both federal USP standards and New York State Board of Pharmacy requirements [5].

503A pharmacies compound for individual patients based on a valid, patient-specific prescription from a licensed prescriber. They are not permitted to compound large batches for office use under the 503A framework. The New York State Board of Pharmacy enforces registration, sterile and non-sterile compounding standards, and beyond-use dating requirements under 8 NYCRR Part 29.

Compounded flibanserin is typically formulated as a 100 mg oral capsule or troche at a fraction of the $880 brand price. Some New York-based 503A pharmacies price compounded flibanserin at $30 to $80 per month, though this varies by pharmacy. A small number of specialty compounding pharmacies report offering it at no cost under specific patient assistance arrangements.

The key legal distinction New York patients and prescribers must understand: compounding is legal, but the compounding pharmacy cannot use the same active pharmaceutical ingredient (API) source that Sprout uses without complying with USP monograph requirements. Prescribers should verify that a 503A pharmacy is registered with the New York State Board of Pharmacy (search at the NYS OP License Verification portal) before writing a compounding-specific prescription. The FDA's REMS requirement for Addyi brand does not extend to compounded flibanserin, which means a REMS-enrolled prescriber can still write a compounding-directed prescription outside the REMS dispensing framework, though many choose to retain REMS enrollment for documentation purposes.

Insurance plans do not reimburse compounded medications in most cases. The cost advantage of compounding is almost entirely a cash-pay benefit.

Can You Get a Flibanserin Prescription via Telehealth in New York?

Yes. New York permits telehealth prescribing of flibanserin, and multiple national and New York-licensed telehealth platforms now offer this service. The prescriber must hold a New York State medical license and must be enrolled in the Addyi REMS program before issuing the prescription [1].

The REMS enrollment process for prescribers takes approximately 10 to 15 minutes online and requires the prescriber to complete a brief educational attestation confirming they have counseled patients on the alcohol interaction and CYP3A4 drug interaction risk. The FDA's REMS program does not require an in-person visit, so the full prescribing and counseling workflow can occur by video visit.

New York's telehealth parity law (Insurance Law Section 3217-a, implemented for commercial plans) requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits for covered services, which means the prescribing visit cost itself should not be a barrier for insured patients.

From a clinical standpoint, a telehealth prescriber should still conduct a thorough assessment. The North American Menopause Society (NAMS) 2023 position statement notes that "HSDD is underdiagnosed partly because clinicians do not routinely ask about sexual desire in clinical encounters" [6]. A structured video visit using a validated tool such as the Female Sexual Function Index (FSFI) or the Decreased Sexual Desire Screener (DSDS) provides adequate clinical documentation for both REMS purposes and insurance PA.

What Is the Clinical Evidence Behind Flibanserin?

Flibanserin 100 mg nightly earned FDA approval based on three key Phase 3 trials: BEGONIA, VIOLET, and DAISY. All three were 24-week, randomized, double-blind, placebo-controlled trials in premenopausal women with generalized acquired HSDD.

The BEGONIA trial (N=1,378) showed a statistically significant increase in SSEs of 0.7 events per 28 days over placebo (P<0.001) and a reduction in the Female Sexual Distress Scale-Revised (FSDS-R) score of 9.5 points versus 6.2 points for placebo [3]. The effect size is modest by absolute standards but was judged clinically meaningful by the FDA advisory committee because HSDD carries substantial psychological distress burden for affected women.

The VIOLET trial and DAISY trial replicated similar SSE and distress-score improvements, with dropout rates for adverse events of approximately 13% on flibanserin versus 6% on placebo, driven primarily by dizziness, somnolence, nausea, and fatigue [7].

Post-approval pharmacovigilance data through the FDA MedWatch system have not identified a materially different safety profile from the trials in real-world use, though cases of severe hypotension following alcohol co-ingestion have been reported.

The American College of Obstetricians and Gynecologists (ACOG) states in its 2019 Committee Opinion on Female Sexual Dysfunction: "Flibanserin is the only FDA-approved pharmacologic treatment for HSDD in premenopausal women; clinicians should discuss both the modest efficacy and the alcohol interaction risk with patients before prescribing" [4]. That guidance remains the standard reference point for prescribers in New York.

How Flibanserin Works: Mechanism in Plain Language

Flibanserin is not a hormone. It acts centrally as a postsynaptic 5-HT1A agonist and 5-HT2A antagonist, with additional dopamine D4 receptor partial agonism. The net effect is a shift in the balance between serotonin (which suppresses desire) and dopamine and norepinephrine (which promote desire) in the prefrontal cortex and limbic system [8].

This mechanism is entirely different from sildenafil (Viagra), which works peripherally on genital blood flow. Flibanserin targets the neural circuits governing sexual motivation, not arousal physiology. That distinction matters for patient counseling: women will not notice an immediate or dose-related effect. Therapeutic response, when it occurs, typically takes four to eight weeks and requires consistent nightly dosing.

If a patient sees no benefit after eight weeks of adherence, current clinical guidance supports discontinuation rather than dose escalation, because 100 mg nightly is the maximum approved dose.

Decision Framework: Which Cost Path Is Right for a New York Patient?

New York patients in 2026 face four distinct cost pathways, each suited to a different situation.

Path 1: Commercial insurance plus Sprout savings card. Best for patients with employer-sponsored or marketplace plans who can clear PA. Total monthly cost as low as $10 to $50.

Path 2: New York Medicaid with prior authorization. Best for patients enrolled in Medicaid Managed Care. Cost is $0 after approval; the PA process is the main hurdle.

Path 3: Brand cash pay with GoodRx or similar coupon. Rarely the right choice given the $800+ price, but applicable if a patient's insurance explicitly excludes the drug and she does not qualify for the savings card.

Path 4: Compounded flibanserin from a 503A pharmacy. Best for patients who are uninsured or underinsured, whose insurance excludes compounded medications, and who want the lowest possible out-of-pocket cost. Verify pharmacy registration before filling.

Each path requires a REMS-enrolled prescriber. Starting with that prescriber, whether through a telehealth platform or in-person gynecologist, is the first step for all four paths.

Monitoring and Safety Considerations Specific to New York Prescribers

New York prescribers using the Addyi REMS must document patient counseling on three specific points: (1) complete alcohol avoidance within the dosing window, (2) the hypotensive interaction with strong and moderate CYP3A4 inhibitors (fluconazole, ketoconazole, clarithromycin, certain antiretrovirals), and (3) somnolence requiring caution with driving or operating machinery on the night of dosing [1].

The New York State Department of Health's prescribing guidelines for sexual health medications cross-reference the FDA REMS but do not impose additional state-level monitoring requirements beyond standard prescribing documentation in the patient medical record.

For patients taking compounded flibanserin outside the REMS dispensing chain, the prescriber's obligation to counsel on the alcohol and drug interaction risk is identical to that for the branded product. The active molecule is the same.

Follow-up visits at four to eight weeks are standard practice to assess response, tolerability, and alcohol use patterns. A structured question such as "On how many nights in the past 28 days did you take the tablet within two hours of consuming any alcohol?" provides a practical adherence and safety check.